Eli Lilly is heading back to its regular Chinese collaborator Innovent with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders.
- Home |
- Lilly, Innovent pen $8.8B oncology, immunology collab that ‘moves beyond traditional licensing’
Lilly, Innovent pen $8.8B oncology, immunology collab that ‘moves beyond traditional licensing’
- February 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
